

Shanna Dewaele

THERAPEUTIC APPLICATIONS OF *SAMMSON* LNCRNA INHIBITION IN UVEAL MELANOMA

Shanna Dewaele (1,2), Katrien Vanderheyden (1,2), Boel De Paepe (3), Louis Delhay (2,4), Fariba Nemati (5), Didier Decaudin (5), Sven Eyckerman (2,4), Rudy Van Coster (3), Jo Vandesompele (1,2) and Pieter Mestdag (1,2)

- (1) Center for Medical Genetics, Ghent University, Ghent, Belgium
- (2) Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium
- (3) Department of Pediatrics, Division of Pediatric Neurology and Metabolism, Ghent University Hospital, Ghent, Belgium
- (4) Center for Medical Biotechnology, VIB-Ghent University, Ghent, Belgium
- (5) Translational Research Department, Institut Curie, PSL Research University, Paris, France

Uveal melanoma is the most common intraocular malignancy in adults. The lack of an effective treatment results in a median survival time less than one year for patients with metastatic disease. Recently, our lab identified the melanoma-specific long non-coding RNA (lncRNA) *SAMMSON* as a novel therapeutic target in skin melanoma.

Analysis of a PAN cancer RNA-sequencing dataset revealed consistent expression of *SAMMSON* in uveal melanoma tumors. Although *SAMMSON* expression was lower in uveal compared to skin melanoma, over 90% of uveal melanoma tumors showed detectable *SAMMSON* expression. Further analysis also revealed *SAMMSON* expression in conjunctival melanoma, another form of ocular melanoma. To evaluate the therapeutic potential of *SAMMSON* inhibition in uveal and conjunctival melanoma, we treated a panel of representative cell lines with *SAMMSON*-specific antisense oligonucleotides (ASOs) and observed a strong reduction in cell viability, accompanied by induction of apoptosis. These effects were dependent on ASO dosing and were validated using 8 independent *SAMMSON*-targeting ASOs and various ASO chemistries. ASO-treatment of a uveal melanoma PDX model further confirmed the observed phenotype. In line with the function of *SAMMSON* in modulating mitochondrial metabolism, *SAMMSON* knock down resulted in a decreased mitochondrial oxidative phosphorylation. Together, our results demonstrate the efficacy of *SAMMSON* inhibition as a novel treatment option for uveal melanoma patients.